P2Y<sub>12</sub> Receptor Inhibitors in the Treatment of Patients with Acute Coronary Syndrome and Percutaneous Coronary Intervention: Possibilities of Prasugrel
The possibilities of P2Y12 receptor inhibitors application in the treatment of patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) are discussed in the article. The results of 4 registries in which a comparative analysis of the efficacy and safety of prasu...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2019-01-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/1811 |
| _version_ | 1826949614264123392 |
|---|---|
| author | N. M. Vorobyeva |
| author_facet | N. M. Vorobyeva |
| author_sort | N. M. Vorobyeva |
| collection | DOAJ |
| description | The possibilities of P2Y12 receptor inhibitors application in the treatment of patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) are discussed in the article. The results of 4 registries in which a comparative analysis of the efficacy and safety of prasugrel with clopidogrel or ticagrelor was performed, as well as of all 3 P2Y12-receptor inhibitors among themselves, are considered in detail. The feasibility of replacing clopidogrel to prasugrel during the inpatient treatment of patients with ACS and PCI was evaluated additionally in the MULTIPRAC registry. The results of the registries demonstrate that the use of prasugrel in patients with ACS and PCI is associated with a significant reduction in the risk of ischemic complications and mortality with an acceptable risk of bleeding. At the same time, prasugrel was more effective and safer than clopidogrel and at least was non-inferior to ticagrelor, and according to some registries, even surpasses it in a number of indicators. |
| first_indexed | 2024-03-08T14:01:44Z |
| format | Article |
| id | doaj.art-12b86c39e9bd42549c328b9ad279646f |
| institution | Directory Open Access Journal |
| issn | 1819-6446 2225-3653 |
| language | English |
| last_indexed | 2025-02-17T22:17:08Z |
| publishDate | 2019-01-01 |
| publisher | Столичная издательская компания |
| record_format | Article |
| series | Рациональная фармакотерапия в кардиологии |
| spelling | doaj.art-12b86c39e9bd42549c328b9ad279646f2024-12-04T11:48:16ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532019-01-0114693594310.20996/1819-6446-2018-14-6-935-9431560P2Y<sub>12</sub> Receptor Inhibitors in the Treatment of Patients with Acute Coronary Syndrome and Percutaneous Coronary Intervention: Possibilities of PrasugrelN. M. Vorobyeva0Pirogov Russian National Research Medical UniversityThe possibilities of P2Y12 receptor inhibitors application in the treatment of patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) are discussed in the article. The results of 4 registries in which a comparative analysis of the efficacy and safety of prasugrel with clopidogrel or ticagrelor was performed, as well as of all 3 P2Y12-receptor inhibitors among themselves, are considered in detail. The feasibility of replacing clopidogrel to prasugrel during the inpatient treatment of patients with ACS and PCI was evaluated additionally in the MULTIPRAC registry. The results of the registries demonstrate that the use of prasugrel in patients with ACS and PCI is associated with a significant reduction in the risk of ischemic complications and mortality with an acceptable risk of bleeding. At the same time, prasugrel was more effective and safer than clopidogrel and at least was non-inferior to ticagrelor, and according to some registries, even surpasses it in a number of indicators.https://www.rpcardio.online/jour/article/view/1811acute coronary syndromemyocardial infarctionpercutaneous coronary interventionp2y<sub>12</sub> receptor inhibitorsclopidogrelprasugrelticagrelor |
| spellingShingle | N. M. Vorobyeva P2Y<sub>12</sub> Receptor Inhibitors in the Treatment of Patients with Acute Coronary Syndrome and Percutaneous Coronary Intervention: Possibilities of Prasugrel Рациональная фармакотерапия в кардиологии acute coronary syndrome myocardial infarction percutaneous coronary intervention p2y<sub>12</sub> receptor inhibitors clopidogrel prasugrel ticagrelor |
| title | P2Y<sub>12</sub> Receptor Inhibitors in the Treatment of Patients with Acute Coronary Syndrome and Percutaneous Coronary Intervention: Possibilities of Prasugrel |
| title_full | P2Y<sub>12</sub> Receptor Inhibitors in the Treatment of Patients with Acute Coronary Syndrome and Percutaneous Coronary Intervention: Possibilities of Prasugrel |
| title_fullStr | P2Y<sub>12</sub> Receptor Inhibitors in the Treatment of Patients with Acute Coronary Syndrome and Percutaneous Coronary Intervention: Possibilities of Prasugrel |
| title_full_unstemmed | P2Y<sub>12</sub> Receptor Inhibitors in the Treatment of Patients with Acute Coronary Syndrome and Percutaneous Coronary Intervention: Possibilities of Prasugrel |
| title_short | P2Y<sub>12</sub> Receptor Inhibitors in the Treatment of Patients with Acute Coronary Syndrome and Percutaneous Coronary Intervention: Possibilities of Prasugrel |
| title_sort | p2y sub 12 sub receptor inhibitors in the treatment of patients with acute coronary syndrome and percutaneous coronary intervention possibilities of prasugrel |
| topic | acute coronary syndrome myocardial infarction percutaneous coronary intervention p2y<sub>12</sub> receptor inhibitors clopidogrel prasugrel ticagrelor |
| url | https://www.rpcardio.online/jour/article/view/1811 |
| work_keys_str_mv | AT nmvorobyeva p2ysub12subreceptorinhibitorsinthetreatmentofpatientswithacutecoronarysyndromeandpercutaneouscoronaryinterventionpossibilitiesofprasugrel |